Newsroom

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

Read press release

Newsroom Highlights

Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
  • Press Release
Agilent Named to Newsweek's List of America's Greenest Companies 2026
  • Award
From Instruments to Workflows: What Actually Changes When AI Comes to the Lab
  • Article
Agilent Ranks Among World's Best Employers
  • Award
Bringing Great Science to Life - Sustainably
  • 2024 ESG Report
AI is a Transformative Enabler that’s Reshaping How Science is Conducted in Labs
  • Article

Agilent News

Press Releases

More Press Releases

Media Coverage

More Media Coverage

Agilent Social Media

Agilent on LinkedIn

Agilent on Instagram

Agilent Market Segment Videos

Start-to-Finish PFAS Workflows
  • Environmental
Battery Materials Analysis
  • Advanced Materials
Cancer Research Solutions
  • Cancer
Hydrogen Fuel Testing
  • Chemicals and Energy